ArticleProceedings of the National Academy of Sciences of the United States of America2020
β-Cyclodextrin modified Pt(II) metallacycle-based supramolecular hyperbranched polymer assemblies for DOX delivery to liver cancer cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Role of Cyclodextrins in Modulating Stimuli-Responsiveness for Anticancer Drug Delivery.Pharmaceutical research · 2026Review
- Tumor microenvironment-responsive hyperbranched polymers for controlled drug delivery.Journal of pharmaceutical analysis · 2024Review
- Formation of a low-symmetry PdChemical science · 2024Article
- The Role of Cyclodextrin in the Construction of Nanoplatforms: From Structure, Function and Application Perspectives.Pharmaceutics · 2023Review
- Cyclodextrins as eminent constituents in nanoarchitectonics for drug delivery systems.Beilstein journal of nanotechnology · 2023Review
- Cyclodextrin nanoparticles in targeted cancer theranostics.Frontiers in pharmacology · 2023Review
- Visualizing molecular weights differences in supramolecular polymers.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Cyclodextrin nanoparticles for diagnosis and potential cancer therapy: A systematic review.Frontiers in cell and developmental biology · 2022Review
- Anthracene-induced formation of highly twisted metallacycle and its crystal structure and tunable assembly behaviors.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Hierarchical Hydrogels with Ordered Micro-Nano Structures for Cancer-on-a-Chip Construction.Research (Washington, D.C.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Despite the widespread clinical application of chemotherapeutic anticancer drugs, their adverse side effects and inefficient performances remain ongoing issues. A drug delivery system (DDS) designed for a specific cancer may therefore overcome the drawbacks of single chemotherapeutic drugs and provide precise and synergistical cancer treatment by introducing exclusive stimulus responsiveness and combined chemotherapy properties. Herein, we report the design and synthesis of a supramolecular drug delivery assembly 1 constructed by orthogonal self-assembly technique in aqueous media specifically for application in liver cancer therapy. Complex 1 incorporates the β-cyclodextrin host molecule-functionalized organoplatinum(II) metallacycle 2 with two specific stimulus-responsive motifs to the signaling molecule nitric oxide (NO), in addition to the three-armed polyethylene glycol (PEG) functionalized ferrocene 3 with redox responsiveness. With this molecular design, the particularly low critical aggregation concentration (CAC) of assembly 1 allowed encapsulation of the commercial anticancer drug doxorubicin (DOX). Controlled drug release was also achieved by morphological transfer via a sensitive response to the endogenous redox and NO stimuli, which are specifically related to the microenvironment of liver tumor cells. Upon combination of these properties with the anticancer ability from the platinum acceptor, in vitro studies demonstrated that DOX-loaded 1 is able to codeliver anticancer drugs and exhibit therapeutic effectiveness to liver tumor sites via a synergistic effect, thereby revealing a potential DDS platform for precise liver cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.